Natera completed its acquisition of Foresight Diagnostics in a deal structured for $275 million up front with up to $175 million in earnouts, pairing Foresight’s phased‑variant PhasED‑Seq MRD technology with Natera’s Signatera platform. Company statements argue the integration will raise sensitivity for minimal residual disease detection across solid tumors and accelerate adoption in lymphoma, where Foresight has traction. Other coverage framed the transaction as a larger strategic push by Natera to consolidate tumor‑informed MRD capabilities and expand commercial reach. Sources: corporate announcements and analyst notes.